Potential benefits of the irreversible Pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 11, 2002, Pages 11-21

  Allen, Lee F ^a   Lenehan, Peter F ^a   Eiseman, Irene A ^a   Elliott, William L ^a   Fry, David W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEROID; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERSENSITIVITY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIGENE FAMILY; NAUSEA; ONCOGENE NEU; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VOMITING;

EID: 0036316380     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70122-x     Document Type: Conference Paper

References (108)

1. Cyclin D1 in breast cancer
2. Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene
3. Steroid hormone receptors in breast cancer management
4. The biology of tumor metastasis
5. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior
6. HER-2/neu (c-erb-B2) gene and protein in breast cancer
7. The type 1 growth factor receptor family: New ligands and receptors and their role in breast cancer
8. Epidermal growth factor-related peptides and their receptors in human malignancies
9. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
10. The ErbB signaling network: Receptor heterodimerization in development and cancer
11. Growth factors and cancer
12. Tyrphostins as molecular tools and potential antiproliferative drugs
13. EGF-R expression in ductal breast cancer: Proliferation and prognostic implications
14. The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
15. Targeting the epidermal growth factor receptor for therapy of carcinomas
16. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
17. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma
18. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
19. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
20. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors
21. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene
22. Ligand-specific activation of HER4/p180erbB 4, a fourth member of the epidermal growth factor receptor family
23. Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
24. Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit
25. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis
26. Cripto: A novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia
27. Epidermal growth factor-related peptides in the pathogenesis of human breast cancer
28. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay
29. EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3
30. The erbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms
31. EGF family receptors and their ligands in human cancer
32. Untangling the erbB signaling network
33. EGF receptor in neoplasia and metastasis
34. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
35. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer
36. The c-erbB3/HER3 receptor in human cancer
37. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB 3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas
38. ERBB2 oncogene in human breast cancer and its clinical significance
39. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
40. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3
41. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
42. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
43. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 and HER2
44. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
45. Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors
46. Tyrosine kinases inhibition: An approach to drug development
47. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
48. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
49. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter
50. EGF-related peptides and their receptors in mammary gland development
51. EGF-related peptides in the pathophysiology of the mammary gland
52. The combination of in situ hybridization and immunohistochemical analysis: An evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium
53. Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue
54. Expression of the ERBB3 gene product in breast cancer
55. Epidermal growth factor receptor in human breast cancer. Recent results
56. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas
57. The EGF receptor family as targets for cancer therapy
58. Role of tumor markers, cytogenetics
59. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer
60. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
61. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
62. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer
63. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
64. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
65. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
66. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
67. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
68. The erbB-2 oncogene and chemotherapy: A mini-review
69. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy
70. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
71. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
72. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
73. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
74. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
75. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
76. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
77. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
78. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
79. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer
80. Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
81. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial
82. Elevated expression of activated forms of neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer
83. c-erbB3 and c-erbB 4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer
84. Expression of c-erbB3 protein in primary breast carcinomas
85. C-erbB-3 in human breast carcinoma: Expression and relation to prognosis and established prognostic indicators
86. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma-An immunocytochemical study
87. Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells
88. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers
89. c-erbB-4 protein expression in human breast cancer
90. Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer
91. Two erbB-4 transcripts are expressed in normal breast and in most breast cancers
92. Expression of the c-erbB-4/HER 4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types
93. ErbB 4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation
94. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo
95. Specificity within the EGF family/ErbB receptor family signaling network
96. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling
97. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation
98. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members
99. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression
100. c-erbB-2/EGFR as dominant heterodimerization partners determine a mitogenic phenotype in human breast cancer cells
101. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members
102. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases
103. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
104. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells
105. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer
106. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
107. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033
108. A phase 1 clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors